GSE147850 Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted alpha-particle therapy
Contributors : David Ulmert ; Robert J KleinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe used RNA sequencing to analyze the genomic signatures of prostate cancer that progressed after targeted alpha therapy.
Authors: Moussa M, Papatsoris A, Abou Chakra M, Sryropoulou D, Dellis A Abstract INTRODUCTION: Metastatic castration-resistant prostate cancer (CRPC) is a potentially symptomatic disease with an eventual lethal outcome. Novel pharmaceutical agents are continuously studied with encouraging results in CRPC. AREAS COVERED: In this perspective, the authors present established and promising pharmacotherapeutic strategies for the management of CRPC; both with and without metastases. Apart from the different treatment strategies, the authors present the relevant sequence of treatment through disease progression. E...
Publication date: Available online 30 May 2020Source: Annals of Medicine and SurgeryAuthor(s): Francesco Ziglioli, Marco Baciarello, Giada Maspero, Valentina Bellini, Tommaso Bocchialini, Domenico Cavalieri, Elena Giovanna Bignami, Umberto Maestroni
Abstract Identification and clinical translation of routinely tested biomarkers require a complex and multistep workflow. Here, we described a confirmatory process estimating the utility of previously identified candidate tissue miRNAs for diagnosis of prostate cancer (PCa). RNA was isolated from formalin-fixed paraffin-embedded (FFPE) prostate tissue surgically resected from 44 patients with PCa and 24 patients with benign prostate hyperplasia (BPH). Of the 92 RNA samples obtained, 68 represented 42 malignant (PCa) areas and 26 represented nonmalignant (PCa 0%) areas of the prostate tissue sections. The levels of...
The results suggested the potential for this agent to become a new standard for T-suppression in this patient population.
ConclusionsThe increase in a number of genes associated with ribosome biogenesis, translation, and mTOR signaling may be important to evaluate prognosis and determine treatment approach for prostate cancer (PCa). A better understanding of the molecular pathways associated with CSCs may be promising to develop targeted therapies to prolong survival in PCa.
DiscussionThe RCI may be used to aid medical decision making in older Spanish men with PC, especially in those with a high RCI 5 and higher.
An amendment to this paper has been published and can be accessed via the original article.
For men with advanced prostate cancer, a new hormone therapy pill works better than standard injections -- and carries a much lower risk of heart attack or stroke.
ConclusionOur results on the antitumor effects of ivermectin support its clinical testing.
ConclusionsScreening for ADL impairments is needed for older cancer survivors as Katz ADL disability differs by cancer type, stage, and age with greater impairment with advanced age and stage.Implications for cancer survivorsInterventions to address ADL limitations should be considered for older cancer survivors.